Article Highlight | 16-Jul-2025

Global and Chinese advances in radiopharmaceuticals: Revolutionizing precision medicine in oncology and neurology

Shanghai Jiao Tong University Journal Center

Radiopharmaceuticals have emerged as indispensable tools in modern precision medicine, revolutionizing diagnostic imaging and targeted therapeutic strategies. This review highlights the rapid advancements in the field, with a focus on global trends and China's growing influence as a leader in radiopharmaceutical innovation.

 

Global Market and Trends

The global radiopharmaceutical market is experiencing exponential growth, valued at $812.5 million in 2024 and projected to reach $16.7 billion by 2031, with a CAGR of 10.8%.

 

North America dominates with a 40% market share, followed by Europe (30%) and Asia-Pacific (23%), which has the highest growth potential (CAGR 12.8%).

Regulatory Approvals: Since 2010, there has been a surge in approvals for novel radiopharmaceuticals, particularly in oncology and neurology. Key agents include:

- Diagnostic: 68Ga-DOTATATE (NETSPOT), 68Ga-PSMA-11 (Locametz), and 18F-flortaucipir (Tauvid) for Alzheimer’s.

- Therapeutic: 177Lu-DOTATATE (Lutathera), 223Ra dichloride (Xofigo), and 177Lu-PSMA-617 (Pluvicto).

 

China’s Rapid Growth and Strategic Developments

- China’s radiopharmaceutical market reached $840.96 million in 2024, growing at a CAGR of 12.3%, outpacing the global average.

- The country has 42 approved radiopharmaceuticals, with 32 more in clinical trials, primarily focused on oncology (44.6%), neurology (18.9%), and cardiology (12.2%).

Key Innovations:

- Development of 68Ga-FAPI tracers for cancer imaging.

- Expansion of 177Lu-based therapies for neuroendocrine tumors.

- Exploration of next-generation isotopes like 225Ac and 212Pb for resistant cancers.

Government Support: The "Medical Isotopes Mid- and Long-term Development Plan (2021–2035)" aims to boost domestic production and reduce reliance on imports.

 

Clinical Applications

1. Oncology

- Diagnostic: 18F-FDG PET for tumor metabolism, 68Ga-PSMA-11 for prostate cancer.

- Therapeutic: 177Lu-DOTATATE for neuroendocrine tumors, 223Ra for bone metastases.

2. Neurology

- Diagnostic: 18F-florbetapir (Amyvid) for Alzheimer’s amyloid plaques, 18F-flortaucipir (Tauvid) for tau pathology.

- Therapeutic: Emerging research on α-emitters like 225Ac for glioblastoma.

3. Other Fields

- Cardiology: 99mTc-sestamibi for myocardial perfusion imaging.

- Inflammation/Infection: 68Ga-citrate for detecting infections.

 

Future Directions and Challenges

- AI Integration: Machine learning is accelerating drug discovery, optimizing dosing, and personalizing treatments.

- Novel Ligands & Radionuclides: Bispecific tracers and isotopes like 64Cu (theranostics) are expanding applications.

- Combination Therapies: Merging radiopharmaceuticals with immunotherapy for synergistic effects.

Challenges:

- Production & Supply Chain: Short-lived isotopes require robust logistics.

- Regulatory Hurdles: Harmonizing global standards is critical.

- Cost Barriers: High development expenses limit accessibility in low-resource regions.

 

Conclusion

Radiopharmaceuticals are transforming precision medicine, with China emerging as a major innovator. While challenges remain, advancements in AI, novel isotopes, and international collaboration promise to enhance efficacy, accessibility, and patient outcomes worldwide. The future of radiopharmaceuticals lies in continued innovation, regulatory streamlining, and global partnerships to unlock their full potential in personalized healthcare.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.